LEZERRICA FORD: Open Payments
NPI 1124889829 · CLINTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$929 in 19 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $751 · 2025 $929
Food & beverage: $929
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 3 | $249 |
| Teva Pharmaceuticals USA, Inc. | 3 | $157 |
| Otsuka America Pharmaceutical, Inc. | 2 | $138 |
| Alkermes, Inc. | 4 | $131 |
| Luye Pharma (USA) Ltd. | 1 | $119 |
| Neurocrine BioSciences, Inc. | 3 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
| ABBVIE INC. | 1 | $24 |
Products named: FANAPT, UZEDY, ARISTADA, ERZOFRI EXTENDED-RELEASE, ABILIFY MAINTENA, INGREZZA, CAPLYTA, VRAYLAR.
Industry payments across LA — which companies pay providers there.
